We are live on ! Find out more
DOVA

Dova Pharmaceuticals, Inc. Common Stock
DOVA

Delisted

DOVA was delisted on the 11th of November, 2019.

Back to rankings

59 hedge funds and large institutions have $75.9M invested in Dova Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

538% more call options, than puts

Call options by funds: $804K | Put options by funds: $126K

18% more capital invested

Capital invested by funds: $64.4M → $75.9M (+$11.6M)

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

2% more funds holding

Funds holding: 58 → 59 (+1)

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

Holders
59
Holders Change
+1
Holders Change %
+1.72%
% of All Funds
1.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
17
Reduced
16
Closed
10
Calls
$804K
Puts
$126K
Net Calls
+$678K
Net Calls Change
+$680K

Top Buyers

Rank Fund Capital Flow
1
SMH
Sanders Morris Harris
Texas
+$2.29M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.61M
3
Morgan Stanley
Morgan Stanley
New York
+$1.14M
4
BCM
Bridgeway Capital Management
Texas
+$957K
5
BGIM
Brandywine Global Investment Management
Pennsylvania
+$576K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$2.67M
2
FI
Fosun International
China
-$1.94M
3
SFM
Sphera Funds Management
Israel
-$1.4M
4
Wells Fargo
Wells Fargo
California
-$298K
5
TRCT
Tower Research Capital (TRC)
New York
-$154K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$27.8M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$12M +$89K +10,970 +0.8%
BlackRock
3
BlackRock
New York
$10.3M +$34.2K +4,217 +0.4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$4.58M +$1.61M +198,456 +63%
SMH
5
Sanders Morris Harris
Texas
$2.51M +$2.29M +281,915 New
CS
6
Candriam SCA
Luxembourg
$2.07M – – –
State Street
7
State Street
Massachusetts
$1.91M +$81.5K +10,036 +5%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$1.46M +$67.5K +8,314 +5%
GKIM
9
GW&K Investment Management
Massachusetts
$1.46M -$118K -14,547 -8%
Northern Trust
10
Northern Trust
Illinois
$1.45M -$128K -15,718 -9%
Morgan Stanley
11
Morgan Stanley
New York
$1.43M +$1.14M +140,781 +688%
BCM
12
Bridgeway Capital Management
Texas
$1.05M +$957K +117,856 New
Wells Fargo
13
Wells Fargo
California
$798K -$298K -36,760 -29%
SIM
14
Spark Investment Management
New York
$715K +$157K +19,400 +32%
BGIM
15
Brandywine Global Investment Management
Pennsylvania
$631K +$576K +70,971 New
Charles Schwab
16
Charles Schwab
California
$564K -$44.2K -5,450 -8%
Citigroup
17
Citigroup
New York
$553K -$43.1K -5,315 -8%
BC
18
Birchview Capital
Vermont
$445K +$81.2K +10,000 +25%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$413K -$28.2K -3,469 -7%
Citadel Advisors
20
Citadel Advisors
Florida
$405K +$47.6K +5,860 +15%
DekaBank Deutsche Girozentrale
21
DekaBank Deutsche Girozentrale
Germany
$336K +$19.5K +2,400 +22%
AllianceBernstein
22
AllianceBernstein
Tennessee
$267K +$104K +12,800 +74%
Renaissance Technologies
23
Renaissance Technologies
New York
$229K +$209K +25,800 New
TCIM
24
TIAA CREF Investment Management
New York
$223K – – –
TA
25
Teachers Advisors
New York
$208K +$2.64K +325 +1%
1
2 3

DOVA Hedge Fund Activity: Q1 2019 in Review

59 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q1 2019, worth a combined $75.9M — up 18% from $64.4M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new DOVA positions and 10 closed out — a net gain of 1 holder — while 17 added to existing stakes and 16 trimmed.

The largest buyer was Sanders Morris Harris, opening a new position worth an estimated $2.29M. The largest seller was Broadfin Capital, exiting entirely with an estimated $2.67M sold.

  • 59 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q1 2019, up from 58 in Q4 2018.
  • Funds reported $75.9M of Dova Pharmaceuticals, Inc. Common Stock stock for Q1 2019, up 18% quarter-over-quarter.
  • 11 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 10 closed out, a net change of +1 holder.
  • The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was Sanders Morris Harris, an estimated $2.29M added.
  • The largest Dova Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Broadfin Capital, an estimated $2.67M sold.

Based on aggregated 13F filings for Q1 2019.